Healthcare provider profile · identity verified

Susmitha Narayanan, MD

Family Practice · HARRISBURG, NC · NPI 1871814749

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	238	76
Amlodipine Besylate	Amlodipine Besylate	170	49
Lisinopril	Lisinopril	128	41
Prednisone	Prednisone	117	89
Levothyroxine Sodium	Levothyroxine Sodium	111	33
Meloxicam	Meloxicam	111	28
Pantoprazole Sodium	Pantoprazole Sodium	104	30
Hydrochlorothiazide	Hydrochlorothiazide	100	30
Metformin Hcl	Metformin Hcl	94	27
Fluticasone Propionate	Fluticasone Propionate	92	34
Gabapentin	Gabapentin	92	28
Tramadol Hcl	Tramadol Hcl	81	24
Omeprazole	Omeprazole	75	28
Ozempic	Semaglutide	75	14
Pravastatin Sodium	Pravastatin Sodium	67	21
Rosuvastatin Calcium	Rosuvastatin Calcium	66	18
Furosemide	Furosemide	64	18
Metoprolol Succinate	Metoprolol Succinate	63	17
Albuterol Sulfate Hfa	Albuterol Sulfate	61	25
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	56	17
Alprazolam	Alprazolam	55	21
Potassium Chloride	Potassium Chloride	55	16
Metformin Hcl Er	Metformin Hcl	51	11
Glipizide Er	Glipizide	50	14
Tizanidine Hcl	Tizanidine Hcl	48	14
Venlafaxine Hcl Er	Venlafaxine Hcl	48	suppressed
Famotidine	Famotidine	47	16
Escitalopram Oxalate	Escitalopram Oxalate	44	11
Simvastatin	Simvastatin	44	18
Eliquis	Apixaban	42	suppressed
Bupropion Xl	Bupropion Hcl	41	15
Trazodone Hcl	Trazodone Hcl	40	20
Tamsulosin Hcl	Tamsulosin Hcl	39	14
Zolpidem Tartrate	Zolpidem Tartrate	38	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	37	11
Losartan Potassium	Losartan Potassium	35	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	33	32
Sertraline Hcl	Sertraline Hcl	32	13
Clopidogrel	Clopidogrel Bisulfate	31	suppressed
Montelukast Sodium	Montelukast Sodium	31	11
Trulicity	Dulaglutide	30	suppressed
Carvedilol	Carvedilol	29	suppressed
Mirtazapine	Mirtazapine	28	11
Donepezil Hcl	Donepezil Hcl	26	suppressed
Pregabalin	Pregabalin	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	25	suppressed
Januvia	Sitagliptin Phosphate	25	suppressed
Buspirone Hcl	Buspirone Hcl	24	suppressed
Valsartan	Valsartan	24	suppressed
Fluconazole	Fluconazole	23	15
Metoprolol Tartrate	Metoprolol Tartrate	23	suppressed
Ondansetron Hcl	Ondansetron Hcl	23	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	22	11
Celecoxib	Celecoxib	21	suppressed
Hydralazine Hcl	Hydralazine Hcl	21	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	20	17
Doxycycline Monohydrate	Doxycycline Monohydrate	20	18
Triamcinolone Acetonide	Triamcinolone Acetonide	20	17
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Levofloxacin	Levofloxacin	18	17
Synthroid	Levothyroxine Sodium	18	suppressed
Topiramate	Topiramate	18	suppressed
Clonazepam	Clonazepam	17	suppressed
Glimepiride	Glimepiride	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Alendronate Sodium	Alendronate Sodium	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Allopurinol	Allopurinol	11	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Digoxin	Digoxin	11	suppressed
Finasteride	Finasteride	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error